Exclusivity 'Didn't Require Success,' Amgen Tells DC Circ.
Amgen told a D.C. Circuit panel Thursday that it's entitled to extra exclusivity protection for its lucrative calcium-control drug Sensipar because it fulfilled the U.S. Food and Drug Administration's request to...To view the full article, register now.
Already a subscriber? Click here to view full article